It was November 2012 when Dennis Hartman, a Seattle business executive, managed to pull himself out of bed, force himself to shower for the first time in days and board a plane that would carry him across the country to a clinical trial at the National Institute of Mental Health in Bethesda, Md.
Ketamine can quickly alleviate symptoms of obsessive-compulsive disorder (OCD) in patients with constant intrusive thoughts, and the drug’s effects can last for one to two weeks in certain patients. Researchers reported these findings in a poster presented at the American Psychiatric Association’s (APA) annual meeting.
A recent CBS news segment featured a doctor in Florida talking about his success treating fibromyalgia with intravenous (IV) ketamine, a medication usually used for surgical anesthesia. One of his patients described that her fibromyalgia pain was “virtually eliminated” by this treatment.
A new study published by Mt. Sinai Medical Center has show how the intravenous administration of ketamine can significantly reduce the symptoms of patients with chronic PTSD.